Company Overview
Ra Medical Systems' advanced excimer laser systems are tools for use in the treatment of vascular and dermatological diseases. We believe our products enhance patients' quality of life by restoring blood-flow in arteries and clearing chronic skin conditions.

We currently manufacture and market two lines of products:

**DABRA** is our minimally-invasive excimer laser and disposable catheter system that is used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease, a form of peripheral artery disease, or PAD, both above- and below-the-knee. DABRA breaks down plaque to its fundamental chemistry, such as proteins, lipids and other chemical compounds, eliminating blockages by essentially dissolving them without generating potentially harmful particulates. Unlike many treatments for PAD that may damage the arterial wall, DABRA quickly, photochemically dissolves plaque with minimal vascular trauma.

DABRA has been cleared by the FDA for crossing chronic total occlusions in patients with symptomatic infrapopliteal lower extremity vascular disease and has an intended use for ablation of a channel in occlusive peripheral vascular disease. In addition, DABRA was granted CE mark clearance in September 2016 for the endovascular treatment of infrapopliteal arteries via atherectomy and for crossing total occlusions.

**Pharos Excimer Laser** is a powerful 308 nm ultraviolet-B excimer laser used by physicians as a tool to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis, and leukoderma. Pharos has FDA clearance to market Pharos in the U.S. for those skin conditions and CE mark clearance for use in the treatment of those skin conditions, as well as market clearance in China and South Korea.

---

**Stock Overview**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>RMED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>NYSE</td>
</tr>
<tr>
<td>Market Cap</td>
<td>18.25m</td>
</tr>
<tr>
<td>Last Price</td>
<td>$0.527</td>
</tr>
<tr>
<td>52-Week</td>
<td>$0.345 - $3.67</td>
</tr>
</tbody>
</table>

**Investor Relations**

LHA Investor Relations
Jody Cain
jcain@lhai.com
Kevin McCabe
kmccabe@lhai.com

T: (310) 691-7100

06/05/2020 04:10 PM EDT

---

**Recent News**

Ra Medical Systems Announces Closing of $10.0 Million Public Offering
May 22, 2020, 3:23 PM EDT

Ra Medical Systems Receives Continued Listing Standard Notice from the NYSE
May 22, 2020, 6:50 AM EDT

Ra Medical Systems Announces Pricing of $10.0 Million Public Offering
May 20, 2020, 9:16 AM EDT

---

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.